Skip to content
Screener

Medtronic MDT Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Boston Scientific logo
Boston ScientificBSX
$240M+3.0%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$111.57B-6.1%
Enterprise value$138.83B-5.0%
P/E23.2×-2.3×
P/S3.1×-0.4×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Medtronic’s 10-K, filed June 18, 2026.

Filed
Jun 18, 2026, 4:27 PM EDT
Fiscal year
FY2026
Accession
0001628280-26-044354
(in millions, except share amounts)April 24, 2026April 25, 2025
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,280,177,293 and 1,281,934,628 shares issued and outstanding, respectively——
Additional paid-in capital20,92620,833
Retained earnings32,63831,476
Accumulated other comprehensive loss(4,101)(4,284)
Total shareholders’ equity49,46348,024
Noncontrolling interests609232
Total equity50,07248,256
Total liabilities and equity$93,028$91,680

Item 8. Financial Statements and Supplementary Data

FAQ

What is Medtronic's noncontrolling interests in subsidiaries?
Medtronic (MDT) reported noncontrolling interests in subsidiaries of $609M in Q1 2026.
How has Medtronic's noncontrolling interests in subsidiaries changed year-over-year?
Medtronic's noncontrolling interests in subsidiaries increased by 162.5% year-over-year, from $232M to $609M.
What is the long-term trend for Medtronic's noncontrolling interests in subsidiaries?
Over 5 years (2021 to 2026), Medtronic's noncontrolling interests in subsidiaries has grown at a 28.5% compound annual growth rate (CAGR), from $174M to $609M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Medtronic's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude